Filing Details

Accession Number:
0001415889-18-000120
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-01-24 19:13:26
Reporting Period:
2018-01-23
Accepted Time:
2018-01-24 19:13:26
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1109196 Mabvax Therapeutics Holdings Inc. MBVX Pharmaceutical Preparations (2834) 930987903
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1224096 F Jeffrey Eisenberg 11535 Sorrento Valley Road, Suite 400
San Diego CA 92121
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-01-23 17,444 $0.87 82,556 No 4 S Direct
Common Stock Disposition 2018-01-24 17,998 $0.84 64,558 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. Represents a portion of the number of shares required to be sold by the reporting person to cover estimated tax obligations in connection with the vesting of the RSUs of the reporting person. This sale is mandated by the Issuer's election, as approved by the Board of Directors, under the equity incentive plan to require satisfaction of estimated tax obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
  2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.85 to $0.89 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.86 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.